drugset
Drugs / DMX-200
last change Jul 2026 re-read 3 minutes ago

DMX-200

Developed for
focal segmental glomerulosclerosis · pneumonia
Investigated by
Australian and New Zealand Intensive Care Research Centre · Berry Consultants · Dimerix Bioscience Pty Ltd · Global Coalition for Adaptive Research · Intensive Care National Audit & Research Centre · Medical Research Institute of New Zealand
+6 more · Nat Intensive Care Surveillance - MORU · National University Hospital, Singapore · St. Marianna University School of Medicine · UMC Utrecht · Unity Health · University of Pittsburgh Medical Center

Trials 2

today NCT05183646 · Ph 3 NCT02735707 · Ph 3
201620172018201920202021202220232024202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT05183646 May 2022 → Dec 2029 expected focal segmental glomerulosclerosis Dimerix Bioscience Pty Ltd Recruiting No outcome recorded
Phase 3 NCT02735707 Apr 2016 → Feb 2026 overdue pneumonia UMC Utrecht Recruiting Mixed

Press releases naming this drug 47 releases

DateIssuerRelease
2026-07-09 Dimerix Bioscience Pty Ltd DMX-200 Available To Patients Via Post-Trial Access Pathways dimerix.com ↗
2025-12-15 Dimerix Bioscience Pty Ltd DMX-200 ACTION3 Phase 3 Trial Completes Recruitment dimerix.com ↗
2025-09-30 Dimerix Bioscience Pty Ltd DMX-200 receives Orphan Drug Designation in Japan dimerix.com ↗
2025-05-01 Dimerix Bioscience Pty Ltd Dimerix Licenses DMX-200 in the US dimerix.com ↗
2024-12-30 Dimerix Bioscience Pty Ltd DMX-200 ACTION3 Phase 3 Trial Part 2 Recruitment Complete dimerix.com ↗
2024-05-27 Dimerix Bioscience Pty Ltd Dimerix and Taiba enter into License Agreement for DMX-200 dimerix.com ↗
2023-10-04 Advanz Pharma ADVANZ PHARMA and Dimerix enter into an Exclusive License Agreement to commercialise DMX-200 in Europe, Canada, Australia, and New Zealand advanzpharma.com ↗
2023-07-24 Dimerix Bioscience Pty Ltd DMX-200 FSGS PH3 Kidney Trial Part 1 Outcome set for Q1 CY24 dimerix.com ↗
2022-12-15 Dimerix Bioscience Pty Ltd DMX-200 FSGS Phase 3 Trial Part 1 Recruitment Achieved dimerix.com ↗
2022-06-07 Dimerix Bioscience Pty Ltd New Clinical Trial for DMX-200 in Diabetic Kidney Disease dimerix.com ↗
2022-05-09 Dimerix Bioscience Pty Ltd FDA IND Approval for Phase 3 Study of DMX-200 in FSGS dimerix.com ↗
2022-02-01 Dimerix Bioscience Pty Ltd First Regulatory Approval in Europe for DMX-200 FSGS Study dimerix.com ↗

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as DMX-200 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05183646 ↗
1

NCT02735707 ↗